Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.01 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced in oligodendrocytes (27 nCPM) | 1.00 |
| chemistry Open Targets | reachable by antibody | 0.45 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 3 Parkinson's papers of 42 | 0.82 |
| pathways Reactome | 1 pathway; mostly vesicle traffic | 1.00 |
Knock down and overexpress VPS52 in oligodendrocytes; measure LRRK2 kinase activity (pT73-Rab10) and lysosome position and α-synuclein uptake and myelin basic protein output under oxidative stress.
- Cell type
- oligodendrocytes
- Direction
- Both arms: public data does not say which way helps.
- Molecular readout
- LRRK2 kinase activity (pT73-Rab10) and lysosome position
- Functional readout
- α-synuclein uptake and myelin basic protein output under oxidative stress
- Rule-out
- If neither arm moves LRRK2 kinase activity (pT73-Rab10) by 20% or more against non-targeting and empty-vector controls, across three independent differentiations, the hypothesis is wrong.
- Lab request
- CRISPRi knockdown and lentiviral overexpression of VPS52 in iPSC-derived oligodendrocytes; n = 3 differentiations; readouts: LRRK2 kinase activity (pT73-Rab10) and lysosome position; α-synuclein uptake and myelin basic protein output under oxidative stress. Controls: non-targeting guide, empty vector. About 8 to 10 weeks, most of it differentiation.
Sealed predictions
- VPS52 in dopamine neurons, braak+0.04 (p 0.925) → -0.21 (p 0.581)receipt 11737
- VPS52 in oligodendrocytes, braak+0.40 (p 0.287) → +0.26 (p 0.501)receipt 11736
Swarm cases
receipt 11737: VPS52 in dopamine neurons, braak
- power
- full sample -0.02 (p 0.928, n 18), 95% CI -0.48 to +0.45. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.04 (p 0.888, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.04 (p 0.888, n 18). could be the mix.
- skeptic
- leave-one-out range -0.15 to +0.10, sign flips 5; without severely affected donors -0.02 (p 0.928, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for VPS52 in dopamine neurons.
case closed: nothing better to follow up.
receipt 11736: VPS52 in oligodendrocytes, braak
- power
- full sample +0.32 (p 0.191, n 18), 95% CI -0.17 to +0.69. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.33 (p 0.176, n 18). does not hold up.
- composition
- oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: +0.32 (p 0.191, n 18). could be the mix.
- skeptic
- leave-one-out range +0.22 to +0.47, sign flips 0; without severely affected donors +0.32 (p 0.191, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for VPS52 in oligodendrocytes.
case closed: nothing better to follow up.
Receipts
loading the receipts